TCRT — Alaunos Therapeutics, Inc.
Is TCRT overbought or oversold? Here is the current MarketMoodz read.
Alaunos Therapeutics, Inc. (TCRT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.60. The rating moved from Oversold to Strong Oversold on November 7, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.60
- Last changeMoved from Oversold to Strong Oversold on November 7, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Alaunos Therapeutics, Inc. is a micro‑cap biotech with valuation tied to clinical and partnership catalysts and an unclear near‑term cash runway. The broader market is presently risk‑on for growth, which may help sentiment, but absence of recent public financial disclosures and typical small‑cap dilution risk create material uncertainty. Key near‑term drivers would be any clinical readouts, licensing activity, or financing announcements; downside is primarily from trial failure, funding dilution, or reduced investor appetite in a shift to defensive names. Given elevated execution and funding risk, position sizing should account for high volatility and binary outcomes.
Key factors
- Early-stage biotech profile with limited public financial disclosures available; likely reliance on external financing or partnerships to fund operations.
- Value drivers are primarily clinical and/or partnership catalysts; binary outcomes from trials or licensing deals can rapidly move the stock.
- Macro/sector tone currently favors growth and selective healthcare exposure, which could support risk appetite for small-cap biotechs in near term.
- Convertible-debt and financing environment in biotech could increase dilution pressure for mid/small-cap issuers if cash runway is constrained.
- Small float and low liquidity typical of micro-cap biotechs can magnify price moves around news events.
- Absence of recent major filings or public milestones increases uncertainty about near-term revenue and cash runway.
Risks
- Clinical trial or regulatory setbacks that would materially reduce valuation given limited revenue streams.
- Dilution risk from equity raises or convertible financings if cash runway is insufficient.
- Competition from better-funded pharmaceutical/biotech companies or platform technologies.
- Limited visibility into financial statements and operational runway (no recent EDGAR comparisons available).
- Low liquidity and investor attention can amplify downside on negative news and increase volatility.
- Sector rotation toward large-cap defensive pharma could reduce appetite for small speculative biotech names if risk-off sentiment returns.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for TCRT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.